On Wednesday, Aileron Therapeutics Inc (NASDAQ; ALRN) revealed topline data from Cohort 2 of its Phase 1b trial of safety and ...

Ph.D., President and Chief Executive Officer of Aileron. "Additionally, we saw dose dependent effects in five biomarkers ...

(RTTNews) - Aileron Therapeutics, Inc. (ALRN), Wednesday announced positive topline data from the cohort 2 of Phase 1b study evaluating LTI-03 in patients with idiopathic pulmonary fibrosis (IPF).

Announced promising safety and positive biomarker data from Cohort 2 (5mg BID) of the Phase 1b clinical trial of LTI-03 in idiopathic pulmonary fibrosis (IPF) patients demonstrating dose dependent ...

Aileron Therapeutics (ALRN) announced positive topline data from Cohort 2 of its Phase 1b clinical trial evaluating the safety and tolerability ...

AUSTIN, Texas and NEW YORK, Oct. 31, 2024 /PRNewswire/ -- Aileron Therapeutics, Inc. ("Aileron") (NASDAQ: ALRN), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines ...

Aileron Therapeutics, Inc. (NASDAQ:ALRN – Get Free Report) was the target of a significant decline in short interest in October.As of October 15th, there was short interest totalling 255,600 ...

Advancium will evaluate ALRN-6924 as a potential therapy for retinoblastoma, a rare but devastating pediatric cancer of the eye AUSTIN, Texas and NEW YORK, Oct. 31, 2024 /PRNewswire/ -- Aileron ...

Investigative Ophthalmology & Visual Science, 2023 June;64(8): 1272 Aileron Therapeutics is a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address ...

You have permission to edit this article. Edit Close Activate Subscribe My Account Logout Login/Register ...